



Global Hepatitis B Vaccine (Recombinant) Industry Growth and Trends Forecast to 2032

Industry	Published	Pages	Format
Pharma & Healthcare	2026-01-02	97	PDF

Single User	Multi User	Enterprise
USD 3,450	USD 5,175	USD 6,900

Description

The global Hepatitis B Vaccine (Recombinant) market was valued at US\$ million in 2026 and is projected to reach US\$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hepatitis B Vaccine (Recombinant) is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hepatitis B Vaccine (Recombinant) is projected to increase from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for Hepatitis B Vaccine (Recombinant) is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatitis B Vaccine (Recombinant) include GSK, Shenzhen Kangtai Biological Products, Merck, Serum Institute, Sanofi Pasteur, LG Life Sciences, KM Biologics and Dynavax Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hepatitis B Vaccine (Recombinant) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hepatitis B Vaccine (Recombinant) market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US\$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatitis B Vaccine (Recombinant) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatitis B Vaccine (Recombinant).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hepatitis B Vaccine (Recombinant) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hepatitis B Vaccine (Recombinant) Market by Company

GSK

Shenzhen Kangtai Biological Products

Merck
Serum Institute
Sanofi Pasteur
LG Life Sciences
KM Biologics
Dynavax Technologies

Hepatitis B Vaccine (Recombinant) Segment by Type

10mcg/0.5ml
10mcg/ml

Hepatitis B Vaccine (Recombinant) Segment by Application

Newborn
Adult

Hepatitis B Vaccine (Recombinant) Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccine (Recombinant) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccine (Recombinant) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccine (Recombinant).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3:

Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Sales, revenue of Hepatitis B Vaccine (Recombinant) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5:

Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12:

Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13:

Table of Contents

1 Market Overview

- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
 - 1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Size Estimates and Forecasts (2021-2032)
 - 1.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Estimates and Forecasts (2021-2032)
- 1.3 Hepatitis B Vaccine (Recombinant) Market by Type
 - 1.3.1 10mcg/0.5ml
 - 1.3.2 10mcg/ml
- 1.4 Global Hepatitis B Vaccine (Recombinant) Market Size by Type
 - 1.4.1 Global Hepatitis B Vaccine (Recombinant) Market Size Overview by Type (2021-2032)
 - 1.4.2 Global Hepatitis B Vaccine (Recombinant) Historic Market Size Review by Type (2021-2026)
 - 1.4.3 Global Hepatitis B Vaccine (Recombinant) Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
 - 1.5.1 North America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Type (2021-2026)
 - 1.5.2 Europe Hepatitis B Vaccine (Recombinant) Sales Breakdown by Type (2021-2026)
 - 1.5.3 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Breakdown by Type (2021-2026)
 - 1.5.4 South America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Type (2021-2026)
 - 1.5.5 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Breakdown by Type (2021-2026)

2 Global Market Dynamics

- 2.1 Hepatitis B Vaccine (Recombinant) Industry Trends
- 2.2 Hepatitis B Vaccine (Recombinant) Industry Drivers
- 2.3 Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges
- 2.4 Hepatitis B Vaccine (Recombinant) Industry Restraints

3 Market Competitive Landscape by Company

- 3.1 Global Top Players by Hepatitis B Vaccine (Recombinant) Revenue (2021-2026)
- 3.2 Global Top Players by Hepatitis B Vaccine (Recombinant) Sales (2021-2026)
- 3.3 Global Top Players by Hepatitis B Vaccine (Recombinant) Price (2021-2026)
- 3.4 Global Hepatitis B Vaccine (Recombinant) Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hepatitis B Vaccine (Recombinant) Major Company Production Sites & Headquarters
- 3.6 Global Hepatitis B Vaccine (Recombinant) Company, Product Type & Application
- 3.7 Global Hepatitis B Vaccine (Recombinant) Company Establishment Date
- 3.8 Market Competitive Analysis
 - 3.8.1 Global Hepatitis B Vaccine (Recombinant) Market CR5 and HHI
 - 3.8.2 Global Top 5 and 10 Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue in 2025
 - 3.8.3 2025 Hepatitis B Vaccine (Recombinant) Tier 1, Tier 2, and Tier 3

4 Hepatitis B Vaccine (Recombinant) Regional Status and Outlook

- 4.1 Global Hepatitis B Vaccine (Recombinant) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Hepatitis B Vaccine (Recombinant) Historic Market Size by Region
 - 4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales in Volume by Region (2021-2026)
 - 4.2.2 Global Hepatitis B Vaccine (Recombinant) Sales in Value by Region (2021-2026)
 - 4.2.3 Global Hepatitis B Vaccine (Recombinant) Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Hepatitis B Vaccine (Recombinant) Forecasted Market Size by Region

- 4.3.1 Global Hepatitis B Vaccine (Recombinant) Sales in Volume by Region (2027-2032)
- 4.3.2 Global Hepatitis B Vaccine (Recombinant) Sales in Value by Region (2027-2032)
- 4.3.3 Global Hepatitis B Vaccine (Recombinant) Sales (Volume & Value), Price and Gross Margin (2027-2032)

5 Hepatitis B Vaccine (Recombinant) by Application

- 5.1 Hepatitis B Vaccine (Recombinant) Market by Application
 - 5.1.1 Newborn
 - 5.1.2 Adult
- 5.2 Global Hepatitis B Vaccine (Recombinant) Market Size by Application
 - 5.2.1 Global Hepatitis B Vaccine (Recombinant) Market Size Overview by Application (2021-2032)
 - 5.2.2 Global Hepatitis B Vaccine (Recombinant) Historic Market Size Review by Application (2021-2026)
 - 5.2.3 Global Hepatitis B Vaccine (Recombinant) Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
 - 5.3.1 North America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Application (2021-2026)
 - 5.3.2 Europe Hepatitis B Vaccine (Recombinant) Sales Breakdown by Application (2021-2026)
 - 5.3.3 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Breakdown by Application (2021-2026)
 - 5.3.4 South America Hepatitis B Vaccine (Recombinant) Sales Breakdown by Application (2021-2026)
 - 5.3.5 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Breakdown by Application (2021-2026)

6 Company Profiles

- 6.1 GSK
 - 6.1.1 GSK Company Information
 - 6.1.2 GSK Business Overview
 - 6.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)
 - 6.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
 - 6.1.5 GSK Recent Developments
- 6.2 Shenzhen Kangtai Biological Products
 - 6.2.1 Shenzhen Kangtai Biological Products Company Information
 - 6.2.2 Shenzhen Kangtai Biological Products Business Overview
 - 6.2.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)
 - 6.2.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
 - 6.2.5 Shenzhen Kangtai Biological Products Recent Developments
- 6.3 Merck
 - 6.3.1 Merck Company Information
 - 6.3.2 Merck Business Overview
 - 6.3.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)
 - 6.3.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
 - 6.3.5 Merck Recent Developments
- 6.4 Serum Institute
 - 6.4.1 Serum Institute Company Information
 - 6.4.2 Serum Institute Business Overview
 - 6.4.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)
 - 6.4.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
 - 6.4.5 Serum Institute Recent Developments
- 6.5 Sanofi Pasteur
 - 6.5.1 Sanofi Pasteur Company Information
 - 6.5.2 Sanofi Pasteur Business Overview
 - 6.5.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)

6.5.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio

6.5.5 Sanofi Pasteur Recent Developments

6.6 LG Life Sciences

6.6.1 LG Life Sciences Company Information

6.6.2 LG Life Sciences Business Overview

6.6.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)

6.6.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio

6.6.5 LG Life Sciences Recent Developments

6.7 KM Biologics

6.7.1 KM Biologics Company Information

6.7.2 KM Biologics Business Overview

6.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)

6.7.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio

6.7.5 KM Biologics Recent Developments

6.8 Dynavax Technologies

6.8.1 Dynavax Technologies Company Information

6.8.2 Dynavax Technologies Business Overview

6.8.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2021-2026)

6.8.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio

6.8.5 Dynavax Technologies Recent Developments

7 North America by Country

7.1 North America Hepatitis B Vaccine (Recombinant) Sales by Country

7.1.1 North America Hepatitis B Vaccine (Recombinant) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

7.1.2 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)

7.1.3 North America Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032)

7.2 North America Hepatitis B Vaccine (Recombinant) Market Size by Country

7.2.1 North America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

7.2.2 North America Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026)

7.2.3 North America Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032)

8 Europe by Country

8.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Country

8.1.1 Europe Hepatitis B Vaccine (Recombinant) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

8.1.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)

8.1.3 Europe Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032)

8.2 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country

8.2.1 Europe Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

8.2.2 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026)

8.2.3 Europe Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032)

9 Asia-Pacific by Country

9.1 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Country

9.1.1 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

9.1.2 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)

9.1.3 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032)

9.2 Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size by Country

9.2.1 Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032

- 9.2.2 Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032)

10 South America by Country

- 10.1 South America Hepatitis B Vaccine (Recombinant) Sales by Country
 - 10.1.1 South America Hepatitis B Vaccine (Recombinant) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
 - 10.1.2 South America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)
 - 10.1.3 South America Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032)
- 10.2 South America Hepatitis B Vaccine (Recombinant) Market Size by Country
 - 10.2.1 South America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
 - 10.2.2 South America Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026)
 - 10.2.3 South America Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032)

11 Middle East and Africa by Country

- 11.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country
 - 11.1.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
 - 11.1.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)
 - 11.1.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country
 - 11.2.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
 - 11.2.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026)
 - 11.2.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032)

12 Value Chain and Sales Channels Analysis

- 12.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
 - 12.1.1 Hepatitis B Vaccine (Recombinant) Key Raw Materials
 - 12.1.2 Key Raw Materials Price
 - 12.1.3 Raw Materials Key Suppliers
 - 12.1.4 Manufacturing Cost Structure
 - 12.1.5 Hepatitis B Vaccine (Recombinant) Production Mode & Process
- 12.2 Hepatitis B Vaccine (Recombinant) Sales Channels Analysis
 - 12.2.1 Direct Comparison with Distribution Share
 - 12.2.2 Hepatitis B Vaccine (Recombinant) Distributors
 - 12.2.3 Hepatitis B Vaccine (Recombinant) Customers

13 Concluding Insights

14 Appendix

- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
 - 14.5.1 Secondary Sources
 - 14.5.2 Primary Sources
- 14.6 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Major Company of 10mcg/0.5ml
- Table 2: Major Company of 10mcg/ml
- Table 3: Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 5: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type (2021-2026)
- Table 6: Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 7: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type (2021-2026)
- Table 8: Global Hepatitis B Vaccine (Recombinant) Price by Type (2021-2026) & (US\$/Unit)
- Table 9: Global Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (W Units)
- Table 10: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type (2027-2032)
- Table 11: Global Hepatitis B Vaccine (Recombinant) Sales by Type (2027-2032) & (US\$ Million)
- Table 12: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type (2027-2032)
- Table 13: Global Hepatitis B Vaccine (Recombinant) Price by Type (2027-2032) & (US\$/Unit)
- Table 14: North America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 15: North America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 16: Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 17: Europe Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 18: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 19: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 20: Latin America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 21: Latin America Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 22: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (W Units)
- Table 23: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2026) & (US\$ Million)
- Table 24: Hepatitis B Vaccine (Recombinant) Industry Trends
- Table 25: Hepatitis B Vaccine (Recombinant) Industry Drivers
- Table 26: Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges
- Table 27: Hepatitis B Vaccine (Recombinant) Industry Restraints
- Table 28: Global Hepatitis B Vaccine (Recombinant) Sales Revenue by Company (US\$ Million) & (2021-2026)
- Table 29: Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company (2021-2026)
- Table 30: Global Hepatitis B Vaccine (Recombinant) Sales by Company (2021-2026) & (W Units)
- Table 31: Global Hepatitis B Vaccine (Recombinant) Sales Share by Company (2021-2026)
- Table 32: Global Hepatitis B Vaccine (Recombinant) Market Price by Company (2021-2026) & (US\$/Unit)
- Table 33: Global Hepatitis B Vaccine (Recombinant) Industry Company Ranking, 2024 VS 2025 VS 2026
- Table 34: Global Hepatitis B Vaccine (Recombinant) Major Company Production Sites and Headquarters
- Table 35: Global Hepatitis B Vaccine (Recombinant) Company, Product Type & Application
- Table 36: Global Hepatitis B Vaccine (Recombinant) Company Establishment Date
- Table 37: Global Company Market Concentration Ratio (CR5 and HHI)
- Table 38: Global Hepatitis B Vaccine (Recombinant) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 39: Global Hepatitis B Vaccine (Recombinant) Market Size Comparison by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 40: Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026) & (W Units)
- Table 41: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Region (2021-2026)
- Table 42: Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026) & (US\$ Million)
- Table 43: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Region (2021-2026)
- Table 44: Global Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 45: Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032) & (W Units)
- Table 46: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Region (2027-2032)
- Table 47: Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032) & (US\$ Million)
- Table 48: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Region (2027-2032)
- Table 49: Global Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2027-2032)
- Table 50: Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 51: Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 52: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application (2021-2026)

- Table 53: Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 54: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application (2021-2026)
- Table 55: Global Hepatitis B Vaccine (Recombinant) Price by Application (2021-2026) & (US\$/Unit)
- Table 56: Global Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (W Units)
- Table 57: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application (2027-2032)
- Table 58: Global Hepatitis B Vaccine (Recombinant) Sales by Application (2027-2032) & (US\$ Million)
- Table 59: Global Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application (2027-2032)
- Table 60: Global Hepatitis B Vaccine (Recombinant) Price by Application (2027-2032) & (US\$/Unit)
- Table 61: North America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 62: North America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 63: Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 64: Europe Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 65: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 66: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 67: Latin America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 68: Latin America Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 69: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (W Units)
- Table 70: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2026) & (US\$ Million)
- Table 71: GSK Company Information
- Table 72: GSK Business Overview
- Table 73: GSK Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 74: GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 75: GSK Recent Development
- Table 76: Shenzhen Kangtai Biological Products Company Information
- Table 77: Shenzhen Kangtai Biological Products Business Overview
- Table 78: Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 79: Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 80: Shenzhen Kangtai Biological Products Recent Development
- Table 81: Merck Company Information
- Table 82: Merck Business Overview
- Table 83: Merck Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 84: Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 85: Merck Recent Development
- Table 86: Serum Institute Company Information
- Table 87: Serum Institute Business Overview
- Table 88: Serum Institute Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 89: Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 90: Serum Institute Recent Development
- Table 91: Sanofi Pasteur Company Information
- Table 92: Sanofi Pasteur Business Overview
- Table 93: Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 94: Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 95: Sanofi Pasteur Recent Development
- Table 96: LG Life Sciences Company Information
- Table 97: LG Life Sciences Business Overview
- Table 98: LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 99: LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 100: LG Life Sciences Recent Development
- Table 101: KM Biologics Company Information
- Table 102: KM Biologics Business Overview
- Table 103: KM Biologics Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 104: KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
- Table 105: KM Biologics Recent Development
- Table 106: Dynavax Technologies Company Information
- Table 107: Dynavax Technologies Business Overview
- Table 108: Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 109: Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio

- Table 110: Dynavax Technologies Recent Development
- Table 111: North America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032
- Table 112: North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units)
- Table 113: North America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026)
- Table 114: North America Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032) & (W Units)
- Table 115: North America Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Country (2027-2032)
- Table 116: North America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (US\$ Million): 2021 VS 2025 VS 2032
- Table 117: North America Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026) & (US\$ Million)
- Table 118: North America Hepatitis B Vaccine (Recombinant) Market Share by Country (2021-2026)
- Table 119: North America Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032) & (US\$ Million)
- Table 120: North America Hepatitis B Vaccine (Recombinant) Market Share Forecast by Country (2027-2032)
- Table 121: Europe Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032
- Table 122: Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units)
- Table 123: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026)
- Table 124: Europe Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032) & (W Units)
- Table 125: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Country (2027-2032)
- Table 126: Europe Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (US\$ Million): 2021 VS 2025 VS 2032
- Table 127: Europe Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026) & (US\$ Million)
- Table 128: Europe Hepatitis B Vaccine (Recombinant) Market Share by Country (2021-2026)
- Table 129: Europe Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032) & (US\$ Million)
- Table 130: Europe Hepatitis B Vaccine (Recombinant) Market Share Forecast by Country (2027-2032)
- Table 131: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032
- Table 132: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units)
- Table 133: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026)
- Table 134: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032) & (W Units)
- Table 135: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Country (2027-2032)
- Table 136: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (US\$ Million): 2021 VS 2025 VS 2032
- Table 137: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026) & (US\$ Million)
- Table 138: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Share by Country (2021-2026)
- Table 139: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032) & (US\$ Million)
- Table 140: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Share Forecast by Country (2027-2032)
- Table 141: Latin America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032
- Table 142: Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units)
- Table 143: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026)
- Table 144: Latin America Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032) & (W Units)
- Table 145: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Country (2027-2032)
- Table 146: Latin America Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (US\$ Million): 2021 VS 2025 VS 2032
- Table 147: Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026) & (US\$ Million)
- Table 148: Latin America Hepatitis B Vaccine (Recombinant) Market Share by Country (2021-2026)
- Table 149: Latin America Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032) & (US\$ Million)
- Table 150: Latin America Hepatitis B Vaccine (Recombinant) Market Share Forecast by Country (2027-2032)
- Table 151: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032
- Table 152: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units)
- Table 153: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026)
- Table 154: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Forecast by Country (2027-2032) & (W Units)
- Table 155: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Country (2027-2032)
- Table 156: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size Growth Rate (CAGR) by Country (US\$ Million): 2021 VS 2025 VS 2032
- Table 157: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country (2021-2026) & (US\$ Million)
- Table 158: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Share by Country (2021-2026)
- Table 159: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size Forecast by Country (2027-2032) & (US\$ Million)
- Table 160: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Share Forecast by Country (2027-2032)
- Table 161: Key Raw Materials
- Table 162: Raw Materials Key Suppliers
- Table 163: Hepatitis B Vaccine (Recombinant) Distributors List

- Table 164: Hepatitis B Vaccine (Recombinant) Customers List
- Table 165: Research Programs/Design for This Report
- Table 166: Authors List of This Report
- Table 167: Secondary Sources
- Table 168: Primary Sources

List of Figures:

- Figure 1: Hepatitis B Vaccine (Recombinant) Image
- Figure 2: Global Hepatitis B Vaccine (Recombinant) Market Size (US\$ Million), 2021 VS 2025 VS 2032
- Figure 3: Global Hepatitis B Vaccine (Recombinant) Market Size (2021-2032) & (US\$ Million)
- Figure 4: Global Hepatitis B Vaccine (Recombinant) Sales (2021-2032) & (W Units)
- Figure 5: 10mcg/0.5ml Image
- Figure 6: Global 10mcg/0.5ml Sales YoY Growth (2021-2032) & (W Units)
- Figure 7: 10mcg/ml Image
- Figure 8: Global 10mcg/ml Sales YoY Growth (2021-2032) & (W Units)
- Figure 9: Global Hepatitis B Vaccine (Recombinant) Market Size Overview by Type (2021-2032) & (US\$ Million)
- Figure 10: Global Hepatitis B Vaccine (Recombinant) Market Share by Type 2025 VS 2032
- Figure 11: North America Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type in 2025
- Figure 12: North America Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type in 2025
- Figure 13: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type in 2025
- Figure 14: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type in 2025
- Figure 15: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type in 2025
- Figure 16: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type in 2025
- Figure 17: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type in 2025
- Figure 18: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type in 2025
- Figure 19: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Type in 2025
- Figure 20: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Type in 2025
- Figure 21: Global Top 5 and 10 Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue in 2025
- Figure 22: Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: Newborn Image
- Figure 24: Global Newborn Sales YoY Growth (2021-2032) & (W Units)
- Figure 25: Adult Image
- Figure 26: Global Adult Sales YoY Growth (2021-2032) & (W Units)
- Figure 27: Global Hepatitis B Vaccine (Recombinant) Market Size Overview by Application (2021-2032) & (US\$ Million)
- Figure 28: Global Hepatitis B Vaccine (Recombinant) Market Share by Application 2025 VS 2032
- Figure 29: North America Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application in 2025
- Figure 30: North America Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application in 2025
- Figure 31: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application in 2025
- Figure 32: Europe Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application in 2025
- Figure 33: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application in 2025
- Figure 34: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application in 2025
- Figure 35: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application in 2025
- Figure 36: Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application in 2025
- Figure 37: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share in Volume by Application in 2025
- Figure 38: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share in Value by Application in 2025
- Figure 39: North America Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units)
- Figure 40: North America Hepatitis B Vaccine (Recombinant) Sales Share by Country: 2021 VS 2025 VS 2032
- Figure 41: North America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 42: North America Hepatitis B Vaccine (Recombinant) Market Share by Country: 2021 VS 2025 VS 2032
- Figure 43: Europe Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units)
- Figure 44: Europe Hepatitis B Vaccine (Recombinant) Sales Share by Country: 2021 VS 2025 VS 2032
- Figure 45: Europe Hepatitis B Vaccine (Recombinant) Market Size by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 46: Europe Hepatitis B Vaccine (Recombinant) Market Share by Country: 2021 VS 2025 VS 2032
- Figure 47: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units)
- Figure 48: Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Share by Country: 2021 VS 2025 VS 2032
- Figure 49: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Size by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 50: Asia-Pacific Hepatitis B Vaccine (Recombinant) Market Share by Country: 2021 VS 2025 VS 2032
- Figure 51: Latin America Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units)
- Figure 52: Latin America Hepatitis B Vaccine (Recombinant) Sales Share by Country: 2021 VS 2025 VS 2032
- Figure 53: Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 54: Latin America Hepatitis B Vaccine (Recombinant) Market Share by Country: 2021 VS 2025 VS 2032
- Figure 55: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units)
- Figure 56: Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Share by Country: 2021 VS 2025 VS 2032

- Figure 57: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 58: Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Share by Country: 2021 VS 2025 VS 2032
- Figure 59: Hepatitis B Vaccine (Recombinant) Value Chain
- Figure 60: Key Raw Materials Price
- Figure 61: Manufacturing Cost Structure
- Figure 62: Hepatitis B Vaccine (Recombinant) Production Mode & Process
- Figure 63: Direct Comparison with Distribution Share
- Figure 64: Distributors Profiles
- Figure 65: Years Considered
- Figure 66: Research Process
- Figure 67: Key Executives Interviewed